Glucotrack unit submits LT-100 clinical protocol for osteoarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. NDAQ
7. QGEN
8. CSX
9. LRCX
10. BFH

Go back to Glucotrack unit submits LT-100 clinical protocol for osteoarthritis

Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities

September 23, 2026 9:00 AM EDT

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- Lkahi Therapeutics today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets.

A Clear View of Who We Are

A Message From Our CEO, Erik Emerson

Good morning. I'm Erik Emerson, CEO of Lkahi Therapeutics and Glucotrack.

As many of you know, we completed our strategic business combination on July 14. Since then, we have continued to work through the post-closing matters contemplated by the transaction,... More